Patients' characteristics
| Patient no. . | Age, y/sex . | Months from diagnosis . | Platelets (× 109/L) . | Bone marrow . | Bleeding* . | Previous treatment† . |
|---|---|---|---|---|---|---|
| 1 | 66/F | 110 | 15 | Normal | Major skin, mucosal | P, G, A, Sple |
| 2 | 84/F | 78 | 29 | Normal | Minor skin, retinal | P, G, ALG, Sple |
| 3 | 69/F | 108 | 18 | Normal | Minor skin, mucosal | P, G, ALG, Sple |
| 4 | 70/F | 50 | 20 | Normal | Major skin, intestinal | P, G, A, Sple |
| 5 | 56/F | 504 | 10 | Normal | Major skin, mucosal | P, G, C, Sple |
| 6 | 75/M | 168 | 27 | Normal | Minor skin, mucosal | P, C, ALG, Sple |
| 7 | 78/F | 146 | 28 | Normal | Minor skin, intestinal | P, G, C |
| 8 | 64/F | 132 | 3 | Normal | Major skin, mucosal | P, G, A, D, Sple |
| 9 | 42/M | 52 | 27 | Normal | Minor skin, retinal | P, G, C |
| 10 | 68/F | 86 | 12 | Normal | Major skin, menorrhagia | P, G, Sple |
| 11 | 85/F | 46 | 19 | Normal | Minor skin, mucosal | P, G, C |
| 12 | 62/M | 41 | 25 | Normal | Minor skin, mucosal | P, G, C |
| Patient no. . | Age, y/sex . | Months from diagnosis . | Platelets (× 109/L) . | Bone marrow . | Bleeding* . | Previous treatment† . |
|---|---|---|---|---|---|---|
| 1 | 66/F | 110 | 15 | Normal | Major skin, mucosal | P, G, A, Sple |
| 2 | 84/F | 78 | 29 | Normal | Minor skin, retinal | P, G, ALG, Sple |
| 3 | 69/F | 108 | 18 | Normal | Minor skin, mucosal | P, G, ALG, Sple |
| 4 | 70/F | 50 | 20 | Normal | Major skin, intestinal | P, G, A, Sple |
| 5 | 56/F | 504 | 10 | Normal | Major skin, mucosal | P, G, C, Sple |
| 6 | 75/M | 168 | 27 | Normal | Minor skin, mucosal | P, C, ALG, Sple |
| 7 | 78/F | 146 | 28 | Normal | Minor skin, intestinal | P, G, C |
| 8 | 64/F | 132 | 3 | Normal | Major skin, mucosal | P, G, A, D, Sple |
| 9 | 42/M | 52 | 27 | Normal | Minor skin, retinal | P, G, C |
| 10 | 68/F | 86 | 12 | Normal | Major skin, menorrhagia | P, G, Sple |
| 11 | 85/F | 46 | 19 | Normal | Minor skin, mucosal | P, G, C |
| 12 | 62/M | 41 | 25 | Normal | Minor skin, mucosal | P, G, C |
P indicates prednisone; G, γ-globulins; A, azathioprine; Sple, splenectomy; ALG, antilymphocyte globulin; C, cyclophosphamide; and D, danazol.
Major skin indicates diffuse ecchymosis; mucosal, intrabuccal hemorrhagic vesicles or prolonged epistaxis; and intestinal and menorrhagia, gastrointestinal and genitourinary bleeding, respectively.
All patients took prednisone before starting cyclosporin A therapy.